Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.

João Pedro Machado Ribeiro Jacintho Silva et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 439 people · 2026

Range includes no effect

−15%−30% to +4%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.70–1.04

the abstract, start to end

… with GLP-1 receptor agonists (HR 0.85, 95% CI 0.70-1.04; I …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.850.70–1.04

GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsCardiovascular events

1 / 3

2026

this paperpooled itcites it